Rapid IL-4 production by Leishmania homolog of mammalian RACK1-reactive CD4+ T cells in resistant mice treated once with anti-IL-12 or -IFN-γ antibodies at the onset of infection with Leishmania major instructs Th2 cell development, resulting in nonhealing lesions

被引:21
|
作者
Launois, P
Gumy, A
Himmelrich, H
Locksley, RM
Röcken, M
Louis, JA [1 ]
机构
[1] Univ Lausanne, Inst Biochem, World Hlth Org Immunol Res & Training Ctr, CH-1066 Epalinges, Switzerland
[2] Univ Calif San Francisco, Dept Med & Microbiol, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Immunol, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA
[5] Univ Munich, Dept Dermatol, Munich, Germany
来源
JOURNAL OF IMMUNOLOGY | 2002年 / 168卷 / 09期
关键词
D O I
10.4049/jimmunol.168.9.4628
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Rapid production of IL-4 by Leishmania homolog of mammalian RACK1 (LACK)-reactive CD4(+) T cells expressing the Vbeta4-Valpha8 TCR chains has been shown to drive aberrant Th2 cell development and susceptibility to Leishmania major in BALB/e mice. In contrast, mice from resistant strains fail to express this early IL-4 response. However, administration of either anti-IL-12 or -IFN-gamma at the initiation of infection allows the expression of this early IL-4 response in resistant mice. In this work we show that Leishmania homolog of mammalian RACK1-reactive CD4(+) T cells also expressing the Vbeta4-Valpha8 TCR chains are the source of the early IL-4 response to L. major in resistant mice given anti-IL-12 or -IFN-gamma Abs only at the onset of infection. Strikingly, these cells were found to be required for the reversal of the natural resistance of C57BL/6 mice following a single administration of anti-IL-12 or -IFN-gamma Abs. Together these results suggest that a deficiency in mechanisms capable of down-regulating the early IL-4 response to L. major contributes to the exquisite susceptibility of BALB/c mice to L. major.
引用
收藏
页码:4628 / 4635
页数:8
相关论文
共 6 条
  • [1] Maintenance of IL-12-responsive CD4+ T cells during a Th2 response in Leishmania major-infected mice
    Hondowicz, BD
    Park, AY
    Elloso, MM
    Scott, P
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2000, 30 (07) : 2007 - 2014
  • [2] InBALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease
    Himmelrich, H
    Launois, P
    Maillard, I
    Biedermann, T
    Tacchini-Cottier, F
    Locksley, RM
    Röcken, M
    Louis, JA
    JOURNAL OF IMMUNOLOGY, 2000, 164 (09): : 4819 - 4825
  • [3] Functional plasticity of the LACK-reactive Vβ4-Vα8 CD4+ T cells normally producing the early IL-4 instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice
    Maillard, I
    Launois, P
    Himmelrich, H
    Acha-Orbea, H
    Diggelmann, H
    Locksley, RM
    Louis, JA
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2001, 31 (04) : 1288 - 1296
  • [4] The IL-4 rapidly produced in BALB/c mice after infection with Leishmania major down-regulates IL-12 receptor β2-chain expression on CD4+ T cells resulting in a state of unresponsiveness to IL-12
    Himmelrich, H
    Parra-Lopez, C
    Tacchini-Cottier, F
    Louis, JA
    Launois, P
    JOURNAL OF IMMUNOLOGY, 1998, 161 (11): : 6156 - 6163
  • [5] The early IL-4 response to Leishmania major and the resulting Th2 cell maturation steering progressive disease in BALB/c mice are subject to the control of regulatory CD4+CD25+ T cells
    Aseffa, A
    Gumy, A
    Launois, P
    MacDonald, HR
    Louis, JA
    Tacchini-Cottier, F
    JOURNAL OF IMMUNOLOGY, 2002, 169 (06): : 3232 - 3241
  • [6] Anti-Leishmania effector functions of CD4+ Th1 cells and early events instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice
    Louis, JA
    Conceiçao-Silva, F
    Himmelrich, H
    Tacchini-Cottier, F
    Launois, P
    MECHANISMS OF LYMPHOCYTE ACTIVATION AND IMMUNE REGULATION VII: MOLECULAR DETERMINANTS OF MICROBIAL IMMUNITY, 1998, 452 : 53 - 60